Please login to the form below

Not currently logged in
Email:
Password:

Ariad Pharmaceuticals

This page shows the latest Ariad Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

DDB Remedy and McCann Health among 2016 Rx Club winners

DDB Remedy and McCann Health among 2016 Rx Club winners

Ogilvy CommonHealth Worldwide won the gold prize in the drug education - doctors category, taking home the creativity excellence award for its 'ALK Progression' campaign for Ariad Pharmaceuticals.

Latest news

  • Angelini to market Ariad’s Iclusig in Eastern Europe Angelini to market Ariad’s Iclusig in Eastern Europe

    Comes after leukaemia drug passes EMA safety review. US pharma company Ariad Pharmaceuticals has licensed its cancer drug Iclusig to Italy-based firm Angelini Pharma to market in 23 Eastern European ... countries. Angelini will use its Austrian

  • Ariad cuts 160 jobs in US after Iclusig suspension Ariad cuts 160 jobs in US after Iclusig suspension

    Ariad Pharmaceuticals is to cut 40 per cent of its workforce in the US in order to cope with the suspension of its blood cancer drug Iclusig. ... Following the reduction, Ariad will be left with 295 employees covering both regions.

  • Ariad tanks as Iclusig trial is halted on safety grounds Ariad tanks as Iclusig trial is halted on safety grounds

    Shares fall after leukaemia patients develop blood clots.  . Investors continued to bail out of Ariad Pharmaceuticals after it was forced to terminate a pivotal trial of its leukaemia drug Iclusig because ... on the market (albeit with more restrictive

  • Boehringer's oncology unit scores first EU approval Boehringer's oncology unit scores first EU approval

    Meanwhile, other companies are also vying to bring EGFR-targeting drugs to market for NSCLC, including Ariad Pharmaceuticals with its AP26113 candidate (in phase II) and Clovis Oncology with its

  • MSD submits sarcoma drug for US approval

    MSD obtained full rights to ridaforolimus in May 2010 in an agreement with its initial developers, ARIAD Pharmaceuticals, for an upfront payment of $50m plus additional milestone payments. ... ARIAD agreed to co-promote the drug in the US if it is

More from news
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    acquisition of Ariad Pharmaceuticals. ... Company acquisition. Rare diseases, option to R&D pipeline. 30, 000. Ariad Pharmaceuti-cals  . Takeda. Company acquisition. Oncology portfolio including iclusig and brigatinib. 5, 200.

  • Pharma deals in August 2015 Pharma deals in August 2015

    So it was no surprise that by the end of the month Baxalta was rumoured to be countering with deal activity of its own with discussions to buy Ariad Pharmaceuticals, an ... Immuno-oncology combinations in lung cancer. Not disclosed. Peregrine

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 9, 500. Avanir Pharmaceuticals / Otsuka Pharmaceutical. Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect. ... Research collaboration, options to license. 125. ††Ariad Pharmaceuticals / Otsuka Pharmaceutical

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • How to integrate data to drive sales

    Inspired by a recent Agnitio roundtable discussion with Allergan, Ariad Pharmaceuticals,  Astellas and Ipsen Pharma. As the number of our digital channels and tools continually expand, there are many opportunities to

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics